Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2014 · 10-K
Revenue$9.33M$9.33M+14.3% vs Q4 2013 Net Income$668.91K$668.91KN/M vs Q4 2013 EPS Diluted$0.04$0.04N/M vs Q4 2013 Operating Income$946,138N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,722,706N/M Margins · derivedOperating margin10.1%+40.4 pt vs Q4 2013
Net margin7.2%+25.6 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 9, 2015 · 68 d after period end